Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Other Operating Expenses (2016 - 2025)

Marimed has reported Other Operating Expenses over the past 13 years, most recently at $8.0 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 7.78% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.0 million through Dec 2025, up 1.94% year-over-year, with the annual reading at $34.1 million for FY2025, 1.91% up from the prior year.
  • Other Operating Expenses was $8.0 million for Q4 2025 at Marimed, down from $8.0 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $9.6 million in Q1 2025 and troughed at $2.1 million in Q3 2021.
  • The 5-year median for Other Operating Expenses is $7.4 million (2023), against an average of $6.5 million.
  • The largest YoY upside for Other Operating Expenses was 205.93% in 2021 against a maximum downside of 11.49% in 2021.
  • A 5-year view of Other Operating Expenses shows it stood at $3.7 million in 2021, then soared by 140.82% to $8.8 million in 2022, then fell by 6.44% to $8.2 million in 2023, then dropped by 10.21% to $7.4 million in 2024, then rose by 7.78% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Other Operating Expenses are $8.0 million (Q4 2025), $8.0 million (Q3 2025), and $8.4 million (Q2 2025).